Skip to content
PICO Portalanswers from OpenAlex

A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease

PaperCitations, authors & open-access status

A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease is a paper indexed in PICO Portal from OpenAlex.

How many citations does A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease have?

PICO Portalcitation count

A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease has 119 citations in the OpenAlex counts PICO Portal stores.

When was A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease published?

PICO Portalyear

A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease has 2014 year in the PICO Portal index.

What is the open-access status of A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease?

PICO Portaloa status

A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease has bronze oa status in the PICO Portal index.

What is the DOI of A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease?

PICO Portaldoi

The DOI for A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease is on the source record.

What is the PMID of A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease?

PICO Portalpmid

The PMID for A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease is on the source record.

What is the OpenAlex record for A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease?

PICO Portalopenalex

The OpenAlex for A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial